跳至主要内容
临床试验/NCT03014102
NCT03014102Unknown1 期

Recombinant Human Thrombopoietin for Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation

Hongnan Mo1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2016年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
发起方
入组人数
50
试验地点
1
主要终点
the average number of cluster of differentiation 34 positive cells/kg

研究概览

简要总结

The purpose of this study is to determine whether recombinant human thrombopoietin are effective in peripheral blood progenitor cells mobilization for autologous transplantation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • a histologically confirmed diagnosis of Hodgkin's disease, non-Hodgkin's lymphoma, or selected high-risk solid tumors that are planned to receive autologous peripheral blood progenitor cell transplantation
  • Eastern Cooperative Oncology Group performance status of 0 - 2.

排除标准

  • abnormal liver function (aminotransferase or bilirubin levels 2 times upper limit of normal), leukopenia (white blood cell count 3000/L), or a history of platelet or other disorders associated with a bleeding diathesis
  • a history of thromboembolic disease, coronary heart disease,stroke, arrhythmias, central nervous system metastases,or other organ system diseases or abnormalities that might predispose individuals to treatment-related complications

研究组 & 干预措施

TPOqd

Experimental

Recombinant Human Thrombopoietin 300U/kg/d ih quaque die, day-3/-2/-1 before mobilization

干预措施: Recombinant Human Thrombopoietin (Drug)

TPOqod

Active Comparator

Recombinant Human Thrombopoietin 300U/kg/d ih qua altera die, day-3/-1/+2 before mobilization

干预措施: Recombinant Human Thrombopoietin (Drug)

结局指标

主要结局

the average number of cluster of differentiation 34 positive cells/kg

时间窗: up to 24 months

To evaluate the effect of combining various treatment schedules of recombinant human thrombopoietin with granulocyte colony stimulating factor on the mobilization of peripheral blood progenitor cells.

次要结局

未报告次要终点

研究者

发起方
Hongnan Mo
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Hongnan Mo

Attending Physician

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

研究点 (1)

Loading locations...

相似试验